Sidoti Csr Brokers Lower Earnings Estimates for USNA

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti Csr lowered their Q1 2026 earnings per share (EPS) estimates for USANA Health Sciences in a research report issued on Thursday, December 18th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.40 for the quarter, down from their prior forecast of $0.44. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2026 earnings at $0.44 EPS, Q3 2026 earnings at $0.50 EPS, Q4 2026 earnings at $0.56 EPS and FY2026 earnings at $1.90 EPS.

Several other brokerages also recently issued reports on USNA. Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of USANA Health Sciences in a report on Monday, December 8th. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $36.00.

USANA Health Sciences Price Performance

Shares of NYSE USNA opened at $20.31 on Friday. USANA Health Sciences has a 12-month low of $18.48 and a 12-month high of $38.32. The company has a market capitalization of $371.29 million, a PE ratio of 23.08, a price-to-earnings-growth ratio of 0.99 and a beta of 0.66. The firm’s 50-day moving average is $20.04 and its two-hundred day moving average is $26.80.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Thursday, October 9th. The company reported $0.56 EPS for the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. The business had revenue of $200.22 million for the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP raised its holdings in shares of USANA Health Sciences by 349.8% in the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock worth $4,434,000 after purchasing an additional 125,158 shares during the period. Pzena Investment Management LLC increased its position in USANA Health Sciences by 9.4% during the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company’s stock worth $36,583,000 after purchasing an additional 103,074 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in USANA Health Sciences by 202.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,537 shares of the company’s stock valued at $2,978,000 after buying an additional 65,268 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in USANA Health Sciences by 46.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company’s stock valued at $5,084,000 after buying an additional 59,535 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in USANA Health Sciences by 64.6% during the second quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company’s stock worth $4,582,000 after buying an additional 58,921 shares during the period. 54.25% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director John Turman Fleming sold 1,750 shares of the stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $19.79, for a total transaction of $34,632.50. Following the transaction, the director directly owned 4,565 shares in the company, valued at $90,341.35. This represents a 27.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Frederic J. Winssinger sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $19.21, for a total transaction of $38,420.00. Following the completion of the sale, the director owned 5,986 shares of the company’s stock, valued at approximately $114,991.06. The trade was a 25.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,680 shares of company stock worth $114,090 over the last quarter. 0.63% of the stock is currently owned by company insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.